PD-L1 And PIK3CA Testing Market Trends Support A 15.2% CAGR Outlook Through The Forecast Period

The Business Research Company's PD-L1 And PIK3CA Testing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2026 /EINPresswire.com/ -- The market for PD-L1 and PIK3CA testing has seen impressive growth recently, driven by advancements in molecular diagnostics and increasing demand for personalized cancer therapies. As innovations continue and cancer prevalence rises globally, this sector is set to expand even further. Let's delve into the current market size, key growth drivers, significant regional players, and upcoming trends shaping this important diagnostic segment.

Projected Market Growth and Size of the PD-L1 and PIK3CA Testing Market
The PD-L1 and PIK3CA testing market has witnessed rapid expansion in recent years and is anticipated to continue on this upward trajectory. From a valuation of $1.67 billion in 2025, it is expected to reach $1.93 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.5%. This historical growth has been largely fueled by advancements in assay development, increased adoption in clinical trials, rising cancer rates worldwide, progress in molecular diagnostic techniques, and heightened awareness of personalized medicine approaches.

Looking ahead, the market is forecasted to grow significantly, reaching $3.4 billion by 2030 with a CAGR of 15.2%. This expected surge is driven by the integration of artificial intelligence in biomarker detection processes, expanding use of liquid biopsy methods, growth in precision oncology, strategic partnerships between diagnostics firms and pharmaceutical companies, and regulatory approvals for next-generation testing assays. Key market trends over the coming years will include targeted biomarker testing for cancers, AI-based mutation analysis, wider acceptance of liquid biopsy technology, alignment with drug development pipelines, and high-throughput genomic screening.

Download a free sample of the pd-l1 and pik3ca testing market report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28289&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR

Understanding PD-L1 and PIK3CA Testing and Their Importance
PD-L1 and PIK3CA tests are molecular diagnostic tools used to detect specific biomarkers that inform targeted treatment strategies for cancer patients. PD-L1 testing measures the expression of the programmed death-ligand 1 protein on tumor cells, helping to determine the likelihood of response to immunotherapy treatments. Meanwhile, PIK3CA testing identifies mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene, which is crucial for evaluating patient eligibility for therapies targeting the PI3K signaling pathway.

The Growing Cancer Burden as a Key Growth Driver for PD-L1 and PIK3CA Testing
One of the primary forces propelling the PD-L1 and PIK3CA testing market is the rising global incidence of cancer. Cancer is characterized by the uncontrolled growth and spread of abnormal cells that can invade local tissues and metastasize. This increase in cancer cases is largely attributed to lifestyle-related risk factors and aging populations, which lead to more diagnoses and a higher demand for early detection and effective treatment options.
These diagnostic tests play a vital role in cancer management by enabling precise diagnosis and guiding targeted therapies tailored to individual patients, thereby improving clinical outcomes. For example, the American Cancer Society reported in September 2024 that cancer cases among men worldwide are projected to increase by 84% by 2029, growing from 10.3 million in 2022 to 19 million. This significant rise highlights the expanding need for PD-L1 and PIK3CA testing.

View the full pd-l1 and pik3ca testing market report:
https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR

Regional Market Leadership and Growth Prospects in PD-L1 and PIK3CA Testing
In 2025, North America held the largest share of the PD-L1 and PIK3CA testing market. However, the Asia-Pacific region is expected to be the fastest-growing market during the forecast period. The comprehensive market analysis includes regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a global perspective on market dynamics and growth opportunities.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
